廣告
香港股市 將收市,收市時間:6 小時
  • 恒指

    17,815.94
    -273.99 (-1.51%)
     
  • 國指

    6,374.08
    -103.16 (-1.59%)
     
  • 上證綜指

    2,951.97
    -20.56 (-0.69%)
     
  • 滬深300

    3,456.93
    -23.34 (-0.67%)
     
  • 美元

    7.8070
    -0.0020 (-0.03%)
     
  • 人民幣

    0.9304
    +0.0004 (+0.04%)
     
  • 道指

    39,127.80
    +15.64 (+0.04%)
     
  • 標普 500

    5,477.90
    +8.60 (+0.16%)
     
  • 納指

    17,805.16
    +87.50 (+0.49%)
     
  • 日圓

    0.0484
    +0.0001 (+0.21%)
     
  • 歐元

    8.3465
    +0.0082 (+0.10%)
     
  • 英鎊

    9.8590
    +0.0030 (+0.03%)
     
  • 紐約期油

    80.53
    -0.37 (-0.46%)
     
  • 金價

    2,308.70
    -4.50 (-0.19%)
     
  • Bitcoin

    60,824.21
    -1,361.71 (-2.19%)
     
  • CMC Crypto 200

    1,268.28
    -15.51 (-1.21%)
     

Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans

Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans

Neurocrine Biosciences continues to put up really healthy numbers, with an ostensible 335% profit hike on a powerful reversal last quarter. On Friday, Neurocrine Biosciences stock got a Relative Strength (RS) Rating upgrade from 77 to 82. The upgraded 82 RS Rating means Neurocrine Biosciences stock is among the top 18% overall for price performance over the past year.